|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-9-20
|
|
pubmed:abstractText |
This randomized, double-blind, placebo-controlled study evaluated the pharmacodynamic effects of concomitant low-dose aspirin and lumiracoxib in healthy subjects. Participants received lumiracoxib 400 mg once daily (n = 14) or placebo (n = 14) for 11 days, with concomitant low-dose aspirin (75 mg once daily) from days 5 to 11. Ex vivo pharmacodynamic assessments included assays of platelet aggregation and urinary thromboxane and prostacyclin metabolite profile. Arachidonic acid-stimulated platelet aggregation was reduced from 76.3% on day 4 to 4.8% on day 11 in the placebo group and from 75.8% on day 4 to 5.1% on day 11 in the lumiracoxib group. Collagen-induced platelet aggregation was reduced from 77.5% on day 4 to 52.8% on day 11 in the placebo group and from 79.5% on day 4 to 55.9% on day 11 in the lumiracoxib group. Urinary thromboxane and prostacyclin were unaffected by lumiracoxib. In conclusion, concomitant lumiracoxib did not interfere with the cyclooxygenase-1-mediated antiplatelet effects of low-dose aspirin.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Arachidonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Aspirin,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Diclofenac,
http://linkedlifedata.com/resource/pubmed/chemical/Epoprostenol,
http://linkedlifedata.com/resource/pubmed/chemical/Organic Chemicals,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane B2,
http://linkedlifedata.com/resource/pubmed/chemical/lumiracoxib
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0091-2700
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
45
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1172-8
|
|
pubmed:dateRevised |
2009-11-6
|
|
pubmed:meshHeading |
pubmed-meshheading:16172182-Adolescent,
pubmed-meshheading:16172182-Adult,
pubmed-meshheading:16172182-Arachidonic Acid,
pubmed-meshheading:16172182-Aspirin,
pubmed-meshheading:16172182-Collagen,
pubmed-meshheading:16172182-Cyclooxygenase 1,
pubmed-meshheading:16172182-Cyclooxygenase 2,
pubmed-meshheading:16172182-Cyclooxygenase Inhibitors,
pubmed-meshheading:16172182-Diclofenac,
pubmed-meshheading:16172182-Dose-Response Relationship, Drug,
pubmed-meshheading:16172182-Double-Blind Method,
pubmed-meshheading:16172182-Drug Interactions,
pubmed-meshheading:16172182-Epoprostenol,
pubmed-meshheading:16172182-Female,
pubmed-meshheading:16172182-Humans,
pubmed-meshheading:16172182-Male,
pubmed-meshheading:16172182-Middle Aged,
pubmed-meshheading:16172182-Organic Chemicals,
pubmed-meshheading:16172182-Platelet Aggregation,
pubmed-meshheading:16172182-Platelet Aggregation Inhibitors,
pubmed-meshheading:16172182-Thromboxane B2
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects.
|
|
pubmed:affiliation |
Exploratory Clinical Development, Novartis Pharma AG, WSJ-103-4 D, CH-4002 Basel, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
